Living-donor kidney transplantation for a patient with hypoparathyroidism, deafness, and renal dysplasia syndrome

Nobutaka Nishimura, Shunta Hori, Chihiro Omori, Makito Miyake, Satoshi Anai, Kazumasa Torimoto, Katsuya Aoki, Nobumichi Tanaka, Tatsuo Yoneda and Kiyohide Fujimoto

Department of Urology, Nara Medical University, Nara, Japan

**Abbreviations & Acronyms**

CT = computed tomography  
dRTA = distal renal tubular acidosis  
ESRD = end-stage renal disease  
FGF = fibroblast growth factor  
FGFR1c = fibroblast growth factor receptor 1c  
HDR = hypoparathyroidism, sensorineural deafness, and renal dysplasia  
iPTH = intact parathyroid hormone  
LDKT = living-donor kidney transplantation  
POD = postoperative day

**Correspondence**: Nobutaka Nishimura M.D., Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8522, Japan.  
Email: xasaw04200@yahoo.co.jp

**How to cite this article**: Nishimura N, Hori S, Omori C *et al*. Living-donor kidney transplantation for a patient with hypoparathyroidism, deafness, and renal dysplasia syndrome. IJU Case Rep. 2020; 3: 244–247.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Received 2 June 2020; accepted 6 July 2020.  
Online publication 27 July 2020

**Introduction**: Hypoparathyroidism, sensorineural deafness, and renal dysplasia syndrome is an autosomal dominant rare genetic disease. Some patients with hypoparathyroidism, sensorineural deafness, and renal dysplasia syndrome may present with renal calcification (nephrocalcinosis) and disorder. We report the first case of living-donor kidney transplantation for a patient with hypoparathyroidism, sensorineural deafness, and renal dysplasia syndrome.

**Case presentation**: This case pertains to a 26-year-old woman who was diagnosed with congenital hypoparathyroidism 1 month after birth, following which vitamin D supplementation was initiated. In 20XX, she developed nephrocalcinosis and was confirmed to have a GATA3 mutation; hence, she was diagnosed with hypoparathyroidism, sensorineural deafness, and renal dysplasia syndrome. In 20XX + 7, ABO-incompatible living-donor kidney transplantation was performed. Her renal function improved, and graft calcification was not observed.

**Conclusion**: Over intake of vitamin D caused nephrocalcinosis. The renal function was improved after living-donor kidney transplantation and the patient’s serum calcium levels normalized without vitamin D supplementation. Therefore, kidney transplantation should be considered a treatment option for patients with hypoparathyroidism, sensorineural deafness, and renal dysplasia syndrome.

**Key words**: GATA3 mutation, HDR syndrome, kidney transplantation, nephrocalcinosis.

**Keynote message**

HDR syndrome induces nephrocalcinosis, which may result in irreversible renal dysfunction. LDKT is an effective treatment option for patients with HDR syndrome.

**Introduction**

HDR syndrome is a rare autosomal dominant genetic disease caused by GATA3 mutations. Majority of patients who develop HDR syndrome have a long-term history of calcium and/or vitamin D supplementation due to hypocalcemia caused by hypoparathyroidism; some patients also have renal and urinary tract anomalies. Excessive calcium and/or vitamin D supplementation and the abovementioned anomalies often induce renal calcification (nephrocalcinosis), which may result in renal dysfunction. To our knowledge, there are no reports of LDKT in patients with HDR syndrome.

**Case presentation**

A 26-year-old woman had bilateral sensorineural deafness since birth and tonic-clonic seizure 1 month after birth. Her laboratory examination showed severe hypocalcemia and hyperphosphatemia, and serum intact parathyroid hormone levels were undetectable. She was diagnosed with congenital hypoparathyroidism, following which oral vitamin D supplementation was initiated. In,
calcification in bilateral kidneys was detected on abdominal ultrasonography, indicating renal dysfunction (serum creatinine level, 0.8–1.1 mg/dL).

Subsequently, she consulted our institute in October 20XX; the laboratory examination revealed her urine calcium/creatinine (Ca/Cr) ratio was 0.25 and serum iPTH level was 0.2 pg/mL. Abdominal CT revealed severe nephrocalcinosis (Fig. 1). Arterial blood gas analysis was unremarkable and tubular acidosis was not indicated. The urine calcium level was adjusted; her urine Ca/Cr ratio was controlled between 0.2 and 0.3. However, her renal calcification persisted. Thereafter, her renal dysfunction rapidly progressed and she was started on dialysis in February 2013, and LDKT was simultaneously planned. In June 20XX + 1, GATA3 mutation was confirmed by genetic analysis, and she was diagnosed with HDR syndrome.

In January 20XX + 7, ABO-incompatible LDKT was performed. The donor was her mother, who did not have GATA3 mutation. She received double filtration plasmapheresis, plasma exchange, and immunosuppressive regimen, including cyclosporine, mycophenolate mofetil, prednisone, and basiliximab. Rituximab was also administered twice on the day and two weeks before LDKT.

After LDKT, her serum creatinine level continued to decrease (Fig. 2). Her serum and urine calcium level was maintained at a normal range (urine Ca/Cr ratio ≤0.1). Her graft function was fine (serum creatinine 0.9–1.0 mg/dL), and graft calcification was not observed 1 year after LDKT (Fig. 3).

**Discussion**

HDR syndrome is an autosomal dominant genetic disease characterized by the triad of hypoparathyroidism, sensorineural deafness, and renal dysplasia, which was named by Hasegawa et al.1 This is caused by a heterozygous germline mutation of the dual zinc finger transcription factor GATA3, which is located on 10p14-15.2 GATA3 is involved in the embryonic development of the ears, parathyroid glands, and kidneys; hence, its mutation causes triad symptoms. About 62.3% of patients with HDR syndrome have these three signs.5 Congenital hypoparathyroidism is clinically characterized by hypocalcemia, hyperphosphatemia, and inadequate serum iPTH levels. Intake of calcium and/or vitamin D is often indispensable soon after birth because severe hypocalcemia induces tetany, seizure, and hyperreflexia. Sensorineural deafness is often observed immediately after birth; this is bilateral and refractory. Renal dysfunction may also occur in patients with HDR syndrome because of renal and urinary tract anomalies, renal dysplasia, hypoplasia, aplasia, cyst, or vesicoureteral reflex.3,6

Kidney transplantation is the only radical treatment for ESRD. Moreover, kidney transplantation improves survival and reduces the risk of cardiovascular events among patients with ESRD who were placed on a waiting list for transplantation as compared with long-term dialysis.7,8 Nephrocalcinosis is irreversible. Therefore, kidney transplantation could be an effective treatment option for patients with HDR syndrome.
One of the causes of nephrocalcinosis is dRTA. Kato et al. have shown that patients with HDR syndrome have congenital dRTA, which is associated with severe renal calcification. In the present case, arterial blood gas analysis revealed that there was no evidence of acidosis. On the other hand, nephrocalcinosis is associated with increasing in urine calcium. Elevated calcium levels in urine cause calcium deposition on renal tubules, leading to nephrocalcinosis. The patient had received calcium and vitamin D supplementation for 20 years after birth. Therefore, it was considered that her long-term vitamin D supplementation augmented calcium excretion to urine and hypercalciuria caused nephrocalcinosis.

Since she had ESRD and dialysis treatment was introduced, her serum iPTH levels were consistently >300 pg/mL, regardless of congenital hypoparathyroidism (Fig. 4). In the general remarks, hereditary tumoral calcinosis is involved with FGF23. It binds to the receptor complex comprising Klotho and FGFR1c in osteocytes or renal proximal tubules, and has an acceleratory relevance to PTH. In chronic kidney disease, FGF23 and PTH promote the excretion of phosphate in the urine and reduce the serum phosphate level. In the present case, the function of her parathyroid glands was infinitely low due to GATA3 mutation, but hyperphosphatemia by ESRD might intensely activate FGF23 and promote PTH secretion, leading to secondary hyperparathyroidism. After LDKT, serum iPTH levels slightly decreased with renal function improvement, but were mildly high (150–200 pg/mL); hence, tertiary hyperparathyroidism was suspected (Fig. 4).

We should regularly examine serum Ca, P, iPTH. If tertiary hyperparathyroidism persists, the risk of bone-related and cardiovascular events increases, so we consider parathyroidectomy.

It is important that the graft calcification is prevented after LDKT. We should instruct patients with HDR syndrome in dietary habits, and urged her to drink water strictly. It is also necessary to perform image examination such as ultrasonography and CT.

**Conclusion**

We experienced a rare case of LDKT for ESRD due to nephrocalcinosis induced by HDR syndrome. Congenital hypoparathyroidism and ESRD induced chronic hypocalcemia, but renal function improvement after LDKT compensated for the lack of serum calcium. No evidence of graft calcification was observed 1 year after LDKT. However, long-term observation is necessary to determine whether graft calcification occurs in the future.

**Acknowledgment**

The authors thank the patient for her important contribution to this study.

![Fig. 3 Representative image of allograft 12 months after LDKT. Abdominal CT showing that the graft had no calcification 1 year after LDKT. Urine calcium levels gradually decreased after LDKT, and graft calcification did not occur.](image1)

![Fig. 4 Clinical course of serum iPTH and urine Ca/Cr ratio. Her urine Ca/Cr ratio was controlled between 0.2 and 0.3 when she visited our institution. It gradually decreased to ≤0.1 after LDKT. Serum iPTH levels were originally undetectable. Since she had ESRD and dialysis treatment, serum iPTH levels were consistently >300 pg/mL, regardless of congenital hypoparathyroidism.](image2)
Conflict of interest
The authors declare no conflict of interest.

References
1. Hasegawa T, Hasegawa Y, Aso T et al. HDR syndrome (hypoparathyroidism, sensorineural deafness, renal deafness, renal dysplasia) associated with del (10) (p13). Am. J. Med. Genet. 1997; 73: 416–8.
2. Esch HV, Groenen P, Nesbit MA et al. GATA3 haplo insufficiency causes human HDR syndrome. Nature 2000; 406: 419–22.
3. Ali A, Christie PT, Grigorieva IV et al. Functional characterization of GATA3 mutations causing the hypoparathyroidism-deafness-renal (HDR) dysplasia syndrome: insight into mechanisms of DNA binding by the GATA3 transcription factor. Hum. Mol. Genet. 2007; 16: 265–75.
4. Shaw NJ, Haigh D, Lealman GT et al. Autosomal recessive hypoparathyroidism with renal insufficiency and developmental delay. Arch. Dis. Child. 1991; 66: 1191–4.
5. Okawa T, Yoshida M, Usui T et al. A novel loss-of-function mutation of GATA3 (p. R299Q) in a Japanese family with Hypoparathyroidism, Deafness, and Renal Dysplasia (HDR) syndrome. BMC Endocr. Disord. 2015; https://doi.org/10.1186/s12902-015-0065-7.
6. Muroya K, Hasegawa T, Ito Y et al. GATA3 abnormalities and the phenotypic spectrum of HDR syndrome. J. Med. Genet. 2001; 38: 374–80.
7. Wolfe RA, Ashby VB, Milford EL et al. Comparison of mortality in all patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N. Engl. J. Med. 1999; 341: 1725–30.
8. Kasimke BL, Maclean JR, Snyder JL. Acute myocardial infarction and kidney transplantation. J. Am. Soc. Nephrol. 2006; 17: 900–7.
9. Alexander RT, Cordet E, Chambrey R et al. Acidosis and urinary calcium excretion: insights from genetic disorders. J. Am. Soc. Nephrol. 2016; 27: 3511–20.
10. Kato Y, Wada N, Numata A et al. Case of hypoparathyroidism, deafness and renal dysplasia (HDR) syndrome associated with nephrocalcinosis and distal renal tubular acidosis. Int. J. Urol. 2007; 14: 440–2.
11. Sayer JA, Carr G, Simmons NL. Nephrocalcinosis: molecular insights into calcium precipitation within the kidney. Clin. Sci. (Lond). 2004; 106: 549–61.
12. Sprecher E. Familial tumoral calcinosis: from characterization of a rare phenotype to the pathogenesis of ectopic calcification. J. Invest. 2010; 130: 652–60.
13. Ito N, Fukumoto S. Congenital hyperphosphatemic conditions caused by the deficient activity of FGF23. Calcif. Tissue Int. 2020; https://doi.org/10.1007/s00223-020-00659-6.

© 2020 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association 247